Vera Therapeutics, Inc
VERA
NASDAQ
Biotechnology
$31.63
USD
+2.74 (+9.48%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.16B
Volume 5.9M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-401.89M
TTM
-84.1%
YoY
Operating Cash Flow
$-338.65M
TTM
-82.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 21.9 | 27.5 | 34.9 | 39.1 | 52.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 80.1 | 83.9 | 94.2 | 125.1 | 112.5 |
Operating Income | -80.1 | -83.9 | -94.2 | -125.1 | -112.5 |
EBITDA | -80.0 | -83.8 | -94.1 | -125.0 | -112.4 |
Other Income / Expense | -1.0 | -0.1 | -0.5 | -1.4 | -0.7 |
Total Other Income / Expense | 3.5 | 3.6 | 3.1 | 3.2 | 2.8 |
Income Before Income Taxes | -76.7 | -80.3 | -91.1 | -122.0 | -109.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -76.5 | -80.3 | -91.1 | -121.0 | -109.5 |
Consolidated Net Income / Loss | -76.7 | -80.3 | -91.1 | -122.0 | -109.7 |
Net Income Attributable to Common Shareholders | -76.7 | -80.3 | -91.1 | -122.0 | -109.7 |
Basic EPS | -$1.20 | -$1.26 | -$1.39 | -$1.69 | -$1.52 |
Diluted EPS | -$1.20 | -$1.26 | -$1.39 | -$1.69 | -$1.52 |
Basic Shares Outstanding | 63.8M | 63.8M | 65.6M | 71.5M | 71.8M |
Diluted Shares Outstanding | 63.8M | 63.8M | 65.6M | 71.5M | 71.8M |